When first-line treatment isn't enough

Persistent ankle pain after a twist or impact — particularly in an active, younger person — often points to an osteochondral lesion of the talus (OLT): a patch of cartilage and the bone beneath it that has been damaged, usually by trauma. For many patients, an ankle cartilage defect of this kind settles with conservative care: rest, anti-inflammatory medication, bracing, and protected weight-bearing. Published series indicate this approach achieves a satisfactory outcome in roughly half of cases.

For the other half, symptoms persist — stiffness, catching, pain that limits sport or daily activity — and surgical management becomes the next consideration. The usual first step is marrow stimulation, most commonly microfracture, which creates small perforations in the bone beneath the defect to recruit the body's own repair cells. For smaller lesions, this can work well, but size is a decisive factor: Chuckpaiwong et al. (2008) found that lesions reaching 15 mm or more in diameter had only around a 3% success rate with microfracture, while Choi et al. (2009) placed the practical threshold at 150 mm². Above those limits — or where microfracture has already been tried and failed — autologous chondrocyte implantation (ACI) enters the picture as the next step in cartilage restoration.

Why defect size drives the decision to move to ACI

The reason those size thresholds carry such clinical weight comes down to the type of tissue that microfracture actually produces. Rather than regenerating the smooth, load-bearing surface of a healthy joint, marrow stimulation recruits a mix of cell types that form fibrocartilage — a mechanically inferior substitute that tends to soften and break down within two to three years, particularly when it must cover a large surface area. For small, contained lesions this can be an acceptable short-term result, but as defect size increases, the durability of the repair falls away sharply, which is precisely what the studies referenced above demonstrated.

ACI, and its scaffold-based derivatives such as MACI and STACi, take a different biological approach. The aim is to regenerate hyaline-like cartilage rich in type II collagen — the same structural material that makes up native joint surface. This repair tissue is biomechanically closer to what it replaces, and published follow-up series report more sustained outcomes in larger defects as a result. Where a defect already exceeds the range at which marrow stimulation holds up reliably, or where microfracture has been tried and has not delivered lasting relief, these tissue-quality differences form the clinical rationale for moving to cell-based repair rather than repeating a technique the evidence suggests will not hold at that scale.

Who is a suitable candidate

Most patients who reach the referral stage share a recognisable profile: a younger, active individual with a focal, contained lesion on the talar dome, healthy cartilage surrounding the defect, and no significant osteoarthritis elsewhere in the ankle joint. That combination — localised damage in an otherwise well-preserved joint — is the foundation on which ACI candidacy rests.

The factors a specialist will typically weigh include:

• Lesion character — a clearly defined, full-thickness defect with intact surrounding cartilage. Widespread joint degeneration is a contraindication; diffuse osteoarthritis shifts the pathway toward joint preservation or replacement rather than regenerative repair.
• Prior treatment history — failed first-line marrow stimulation (microfracture) is the most common referral trigger, particularly when the defect meets or exceeds the size thresholds where microfracture is unlikely to hold.
• Patient age and activity level — ACI is generally favoured for younger patients with meaningful activity demands; the long recovery commitment is better tolerated, and the durability benefit is more valuable over a longer joint-life horizon.
• Defect size and complexity — classical ACI under a periosteal patch suits a defined size range, but scaffold-based variants such as MACI and STACi extend eligibility to larger or more complex defects that would fall outside that range.

No single factor determines candidacy in isolation. A specialist assessment — combining imaging, clinical examination, and treatment history — is needed to establish whether ACI, a scaffold variant, or an alternative approach best fits the individual presentation.

How the procedure works — classical ACI and scaffold-based options

Two surgical pathways are currently used to deliver ACI for ankle cartilage defects, and understanding the difference helps patients prepare for what a referral is likely to involve.

Classical two-stage ACI

The traditional approach begins with a short arthroscopic procedure to harvest a cartilage biopsy — typically 200–300 mg taken from a non-weight-bearing surface of the joint. The sample is sent to a specialist laboratory, where the chondrocytes are carefully separated and multiplied over several weeks without altering their biological character. Once sufficient cells have been produced, a second open operation reimplants them into the prepared defect, held in place under a periosteal flap or collagen patch that acts as a temporary cover while the new tissue integrates.

For lesions on the inner (medial) surface of the talar dome, where direct surgical access is limited, a medial malleolar osteotomy is often performed — the inner ankle bone is temporarily divided to expose the defect fully, then fixed back securely with screws once implantation is complete. This is a standard access step, not a complication of the procedure.

Single-stage scaffold-based ACI (MACI / STACi)

Modern scaffold variants compress both steps into one operative sitting. The patient's harvested chondrocytes are combined intraoperatively with bone marrow stem cells concentrated from the same surgical field, then seeded onto a three-dimensional collagen scaffold that has been cut to match the exact shape of the defect. There is no laboratory waiting period and no second general anaesthetic.

Giannini et al. (2005) demonstrated that in ankle cases, the detached osteochondral fragment itself can serve as the chondrocyte source — removing the need for a separate donor-site harvest altogether. This ankle-specific refinement reduces procedural burden further.

The specialist will determine which pathway is appropriate based on defect characteristics, lesion location, and the patient's overall clinical picture.

Recovery timeline and what outcomes to expect

A recovery measured in months rather than weeks is the honest expectation for ACI of the ankle — and framing that timeline as the cost of a more durable biological repair, rather than as a drawback, helps patients commit fully to rehabilitation.

After surgery, weight-bearing is initially restricted and reintroduced in carefully staged increments as the implanted tissue matures and begins to integrate with the surrounding cartilage. Return to full activity typically takes 9–18 months. That extended arc reflects the biology: hyaline-like type II collagen repair tissue takes considerably longer to load-condition than the fibrocartilage that microfracture produces — but its structural properties are meaningfully closer to native cartilage, which underpins better long-term durability in larger defects.

Published follow-up studies anchor those long-term expectations. Five-year MACI studies document sustained clinical benefit, and a minimum 10-year outcome study of ACI (Minas et al., Clin Orthop 2014) demonstrated durable results in appropriately selected patients, with a meaningful proportion retaining satisfactory joint function without requiring further major surgery at that point. In younger, active individuals with localised ankle disease, this durability record is the principal argument for regenerative repair over total ankle replacement or arthrodesis — both of which carry greater functional trade-offs at a young age.

One caveat deserves plain statement: most of this long-term evidence comes from knee cohorts. Ankle-specific outcome datasets are promising but smaller, and the 10-year figures seen at scale in knee studies have not yet been replicated in equivalent ankle numbers. Patients and clinicians should calibrate expectations accordingly — the regenerative principle is the same, but ankle-specific data remain more limited.

Accessing ACI in the UK

NHS funding for ankle ACI does not follow automatically from the knee pathway. NICE Technology Appraisal TA477 sets out the criteria under which ACI is recommended on the NHS, but its primary scope is the knee; patients with talar lesions may need their clinician to submit an individual funding request or to pursue treatment privately. Asking the referring clinician specifically about the funding route for ankle cases is a practical first step — and worth raising early, before an extensive workup is complete.

The choice between classical two-stage ACI and a single-stage scaffold option can also affect where treatment is available. The multi-week laboratory interval built into classical ACI requires a centre equipped for that pathway; single-stage scaffold techniques, which have no waiting period between harvest and implantation, are offered more widely. This logistical difference is worth exploring with any specialist under consideration.

Because ankle cartilage repair is technically more demanding than knee repair — access constraints, the risk of osteotomy, and a smaller evidence base all play a role — selecting a clinician with specific ankle cartilage experience matters. For patients working out where to start that search, Search MSK lists cartilage repair specialists across the UK, with filters for region and specialty.